key: cord-0858938-abc34vps
authors: Sivandzadeh, Gholam Reza; Askari, Hassan; Safarpour, Ali Reza; Ejtehadi, Fardad; Raeis-Abdollahi, Ehsan; Vaez Lari, Armaghan; Abazari, Mohammad Foad; Tarkesh, Firoozeh; Bagheri Lankarani, Kamran
title: COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges
date: 2021-08-06
journal: World J Clin Cases
DOI: 10.12998/wjcc.v9.i22.6178
sha: 02bf7523b63288cc4ac5a998449254a8e4559a6a
doc_id: 858938
cord_uid: abc34vps

It is hypothesized that liver impairment caused by coronavirus disease 2019 (COVID-19) infection might play a central role in severe clinical presentations. Liver injury is closely associated with severe disease and, even with antiviral drugs, have a poor prognosis in COVID-19 patients. In addition to the common hepatobiliary disorders caused by COVID-19, patients with pre-existing liver diseases demand special considerations during the current pandemic. Thus, it is vital that upon clinical presentation, patients with concurrent pre-existing liver disease associated with metabolic dysfunction and COVID-19 be managed properly to prevent liver failure. Careful monitoring and early detection of liver damage through biomarkers after hospitalization for COVID-19 is underscored in all cases, particularly in those with pre-existing metabolic liver injury. The purpose of this study was to determine most recent evidence regarding causality, potential risk factors, and challenges, therapeutic options, and management of COVID-19 infection in vulnerable patients with pre-existing liver injury. This review aims to highlight the current frontier of COVID-19 infection and liver injury and the direction of liver injury in these patients.

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly spread across the world[1,2]. The early symptoms of COVID-19 mainly include fever, cough, myalgia, and fatigue. The advanced stages of COVID-19, occurring in up to 15% of patients, are characterized by dyspnea that may gradually end in acute respiratory distress syndrome (ARDS) or multiple organ failure (MOF) [3] . ARDS is a well-known major complication in patients with COVID-19. Besides the respiratory symptoms, SARS-CoV-2 infection may lead to other conditions including liver injury, which is manifested by hepatobiliary symptoms and enzyme elevation. There are many possible underlying causes of liver injury in COVID-19 patients, such as a severe inflammatory response, anoxia, druginduced liver injury, direct cytotoxicity, as well as the reactivation of pre-existing metabolic liver disease [4] . Liver injury can range from elevation of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin levels to hepatic dysfunction in severe cases of COVID-19 [5] . If liver damage persists, the disease is expected to advance over the patient's entire lifetime. Under septic conditions, the liver is one of the most important organs as it plays an important role in regulating a broad range of physiological processes such as metabolic, homeostatic, and host-defense activities. It has been proposed that metabolic liver dysfunction in severe sepsis is associated with the aggravation of MOF [6] . Given these data, patients with metabolic liver injury, especially those with autoimmune liver disorders or posttransplant immunosuppression, are at increased risk of infection because of their altered immune system. For example, patients with liver cirrhosis are at an increased risk of acute decompensation when affected by bacterial, fungal, or viral infections [7] . Liver symptoms are not atypical among patients with COVID-19 and may appear without any respiratory symptoms. Hepatic symptoms have been reported to be associated with worse clinical outcomes and an increased risk of mortality [8] . However, in patients with metabolic liver diseases, special consideration should be given to changes in the primary condition, and the monitoring and assessment of liver function should be meticulously undertaken during treatment [9] . It is worth studying whether the COVID-19-related liver dysfunction is caused by the viral infection or by other comorbid medical conditions, including hepatotoxic antiviral drugs, the coexistence of systemic inflammatory response, acute hypoxemic respiratory failure, and/or MOF [10] . In this review, we address the liver-related adverse events seen in the current COVID-19 pandemic and associated antiviral drugs by detailing the pathophysiology, etiology, biomarkers, and diagnosis. This study aimed to raise awareness of liver injury in COVID-19 and provide information concerning hepatic management of afflicted patients. PubMed, Scopus, Science Direct, and Google Scholar were searched for studies using the following keywords: "COVID-19", "SARS-CoV-2", "2019-nCoV", "liver diseases", and "hepatobiliary system".

In a systematic review conducted in September 2020, the cumulative prevalence of acute liver injury was estimated at 23.7 (16.1-33.1) per 100 patients with COVID-19 [11] . In another systematic review and meta-analysis, the frequency of liver injury in patients with COVID-19 was reported as 19% (range: 1%-53%). The prevalence of hypoalbuminemia (26.3-30.9 g/L), which is more common among patients with severe disease, was 6%. Also, the pooled prevalence of elevated liver enzymes for ALT, AST, and total bilirubin was estimated to be 18% (13%-25%), 21% (14%-29%), and 6% (3%-11%), respectively [12] . Liver injury is more prevalent among patients with severe COVID-19 than nonsevere cases[13]; its incidence in COVID-19 patients with a fatal outcome is estimated to be between 58% and 78% [14] .

It has been observed that the rise in ALT level during COVID-19 is significantly higher in men as well as younger patients with liver injury according to univariate analysis, though that was not by multivariate analysis [15] . A study in children with COVID-19 and liver injury showed that in addition to a milder course, fewer radiological and laboratory changes were observed in comparison with adults [16] . Also, the probability of a surge in ALT seems to be less likely in children with liver injury than in adults [13, 17, 18] . A systematic review and meta-analysis showed that children under 18 years of age with COVID-19 had a lower rate of liver injury than adults (10%[4-22] vs 18%[8-35] ), although the difference was not statistically significant (P = 0.32) [12] . It seems that males have a higher risk of experiencing acute liver injury due to COVID-19 than females. Direct bilirubin, indirect bilirubin, ALT, alkaline phosphatase (ALP), and gamma-glutamyltransferase (GGT) levels are reportedly higher in male patients with 20] . Hence, that population may be more susceptible to liver damage, and male patients should be closely monitored for this condition.

Hypoalbuminemia has been identified as a predictor of mortality in COVID-19 patients with liver injury [21] . Decreased hepatic albumin synthesis, leakage of albumin from capillaries, increased catabolism due to fever, and nutritional problems are the probable causes of hypoalbuminemia in patients with severe COVID-19 and liver injury [22] .

In terms of ALT and AST, numerous studies have shown that increased levels of these liver enzymes are potential predictors of COVID-19 severity and mortality [12, 15, [22] [23] [24] . In contrast, the results of a case series published as a letter to the editor revealed that increases in the serum concentrations of these two enzymes did not a predict mortality [25] .

Studies in liver transplant recipients with COVID-19 concluded that liver transplantation is not a risk factor for more severe disease during hospitalization. In two studies in Italy, it was observed that the number of liver transplanted patients with COVID-19 was very low, three of 200 patients in the first study, and eight of 640 in the second study. None of these patients required mechanical ventilation during hospitalization [26, 27] .

The severity of COVID-19 was found to be a predictor of liver injury during hospitalization [odds ratio (OR) 2.20, 95% confidence interval (CI): 1.6-3.02; P < 0.001] in both adults and children [6] . Furthermore, younger age and elevated interleukin (IL)-6 or ferritin level have recently been defined as the strongest predictors of liver injury [8] . The risk of liver injury is reportedly higher in COVID-19 patients who develop gastrointestinal (GI) symptoms during their illness, including diarrhea, nausea and vomiting, anorexia, or abdominal pain (OR: 2.71, 95%CI: 1.52-4.83; P = 0.020)[8].

COVID-19 may have both direct and indirect impacts on the hepatobiliary system. The liver biopsy is a procedure that can unravel the pathophysiologic process, disease progression, and prognosis. Liver biopsies are usually done to confirm the presence of viral ribonucleic acid (RNA) in liver tissues, elucidating a direct liver injury mechanism. That SARS-CoV-2 causes direct hepatocyte injury is supported by evidence of cell apoptosis along with ballooned hepatocytes, acidophilic bodies, and lobular inflammation in liver biopsy specimens. The findings are assumed to be a result of direct viral injury [28] . The presence of angiotensin-converting enzyme 2 (ACE2) receptors as a key cell entry receptor for SARS-CoV-2 in cholangiocytes supports a retrograde mode of liver injury following the viral invasion of the bile tree cells [29] . An autopsy examination by Xu et al [16] revealed that SARS-CoV-2 directly contaminated hepatocytes and caused moderate microvascular steatosis and mild hepatic lobular and portal activity [30] . The autopsy results of another COVID-19 fatality revealed that SARS-CoV-2 led to hepatomegaly with dark red, ballooning degeneration along with lobular necrosis and neutrophil infiltration, infiltration of lymphocytes and monocytes in the portal system, sinusoidal dilatation and congestion with microthrombosis[31]. A recent report lends some support to the hypothesis of a potential correlation between expression of the SARS-CoV spike (S) protein and inflammatory responses and hepatitis. At the onset of SARS-CoV infection, host factors elicit an immune response that blocks virus replication, promotes virus removal, and evokes a persistent adaptive immune response against the virus[32]. However, it is important to note that aberrant hepatic biochemistries were also reported in SARS and Middle East respiratory syndrome (MERS) patients, implicating that potential liver damage is closely correlated with coronavirus infections [33, 34] . It is not yet clear whether the liver injury is caused directly by SARS-CoV-2. It is well recognized that SARS-CoV-2 is closely associated with SARS-CoV. The two viruses recognize the same ACE2 receptor and do not solely target the lung [35] . Under physiological states, the liver detoxifies the blood coming from the digestive tract, maintaining immune homeostasis across the gut-liver axis. However, immune homeostasis is disrupted under psychological stress states in patients with severe COVID-19 ( Figure 1 ). The induction of immune responses and severe systemic inflammatory responses in SARS-CoV-2 infection, which are known as the cytokine storm syndrome, can drive damage to many organs, including the gut and liver. Studies have shown that Th17 and CD8 T cells, IL-2, IL-6, IL-7, IL-10, tumor necrosis factor-α, granulocyte-colony stimulating factor, interferon-inducible protein-10, monocyte chemotactic protein 1, and macrophage inflammatory protein 1 alpha are involved in the immune response and inflammation in severe cases of COVID-19[3,36,37]. In addition, aberrant hepatic biochemistry results have been found mostly in patients with severe COVID-19. Stressinduced hepatic damage might be related to hypoxia-reoxygenation, activation of Kupffer cells and oxidative stress, intestinal endotoxemia, sympathetic hyperactivity, and adrenocortical system hyperactivity in patients with COVID-19[31].

Sepsis is typical in cases of severe COVID-19, particularly when patients have gut microbiota imbalance and pre-existing liver cirrhosis [38] . Sepsis is an uncontrolled immune response to an infection, and it causes psychological stress and lifethreatening multiple organ failure [39] . Sepsis-related hepatic damage is associated with ischemia and shock, cholestasis, altered bile metabolism, drug toxicity, and overwhelming inflammation [40] . It has been shown that sepsis in COVID-19 patients might be one of the causes of liver injury and leads to a poor prognosis. Moreover, severe tissue hypoxia and hypovolemic shock due to severe dehydration result in ischemic/hypoxic liver injury in COVID-19 patients. Recent findings suggest that ischemic/hypoxic liver injury caused by SARS-CoV-2 infection is related to metabolic acidosis aggravation, calcium overloading, and alterations in the mitochondrial permeability transition pore protein [41] . Additionally, Zhao et al [42] showed that the expression of SARS-CoV-2 can be detected in patchy areas of the liver duct, implying that hepatic ductal organoids are susceptible to SARS-CoV-2 infection. Furthermore, SARS-CoV-2 infection can also disrupt the barrier and bile acid transporting functions of cholangiocytes, implying that SARS-CoV-2 may directly induce cholangiocyte damage leading to the accumulation of toxic bile acid [42] . In view of the points above, viral infection in COVID-19 patients might directly give rise to liver injury. It has been suggested that if AST, ALT, and total bilirubin levels are very high in COVID-19 patients, the hospital stay might be prolonged [3, 43] . Besides, the reported findings suggest that among patients with aberrant liver function, moderate and severe cases of COVID-19 are more likely to be associated with the occurrence of liver injury (58.8% and 66.7%, respectively)[44]. 

ACE2 is a metalloproteinase regulator of the renin-angiotensin system, which hydrolyzes angiotensin (Ang) II to Ang-(1-7) [45] . The main physiological function of ACE2 is contributing to the regulation of vasoconstriction and blood pressure [46, 47] . Type 2 transmembrane protease serine (TMPRSS2), belonging to the serine protease family, can cleave and activate the coronavirus S protein for membrane fusion [47] [48] [49] . It has been demonstrated that ACE2 and TMPRSS2 are key molecules both for the entry of SARS-CoV and SARS-CoV-2 into host cells and for viral spread in the infected host[50-52]. SARS-CoV-2 cell entry is initiated by specific binding of the S protein to the cellular receptor and S protein priming following proteolytic cleavage by host cell proteases. Moreover, each S protein of SARS-CoV-2 contains two subunits, a globular S1 domain at the N-terminal end, and a membrane-proximal S2 domain that mediates attachment and membrane fusion. Similar to SARS-CoV, SARS-CoV-2 utilizes the receptor-binding motif within the S1 domain to bind to the ACE2 receptor, which facilitates the effects of TMPRSS2 on the cleavage of protein S at two distinct sites, termed S1/S2; viral entry then occurs following cell membrane priming and fusion[51, 53,54]. The S1 subunit is responsible for host cell receptor binding, while the S2 subunit mediates viral and cell membrane fusion [55] . A recent study by Zhou et al [52] demonstrated that SARS-CoV-2 infection depends on the binding of the ACE2 receptor and the S protein. If the S protein is considered as a key, the ACE2 receptor acts like a lock that is unlocked by its key. A group of researchers also found that the S protein of SARS-CoV-2 displays 10 to 20 fold more affinity to the ACE2 receptor than SARS-CoV, which may explain why SARS-CoV-2 is so contagious [56, 57] . Recent studies have determined that the ACE2 receptor and TMPRSS2 are highly expressed not only in lung tissues but also in other organs including the heart, kidney, liver, colon, esophagus, brain, gallbladder, and testis, implying that SARS-CoV-2 might also affect other organs[58,59]. High ACE2 receptor expression was identified in cholangiocytes, with a level 20 fold higher than that in hepatocytes[60]. In addition, researchers have reported that both ACE2 receptors and TMPRSS2 are broadly expressed in the liver [61]. In a recent study, single-cell RNA sequencing analysis and immunohistochemistry confirmed that the ACE2 receptor is predominantly expressed in bile duct epithelial cells [62] . Recently, Seow et al [63] reported that ACE2 receptors and TMPRSS2 are precisely co-expressed in TROP2 + liver progenitors in human hepatic tissue.

The origin of liver damage following COVID-19 infection potentially involves systemic inflammation, viral replication, or drug-related liver injury. Clinical studies indicated a direct association between systemic inflammation with involvement of ferritin, IL-6, and C-reactive protein (CRP), liver injury, and hepatotoxicity [64, 65] . The production of IL-6, a pleiotropic cytokine, may stem from immune cells[66], endothelial cells, fibroblasts, and hepatocytes in response to acute hepatic injury and infection [67] . In line with an important effect of systemic inflammation and specifically IL-6 on liver damage, researchers reported a direct association between acute-phase proteins and IL-6 in COVID-19 patients with increased AST levels. Effenberger et al [67] found that the systemic inflammatory response (SIRS) to SARS-CoV-2 infection in COVID-19 patients was responsible for hepatic injury. In agreement with that, the reported findings suggest more pronounced SIRS in COVID-19 cases with a more acute cytokine release syndrome (CRS), that is, need for intensive care measures. Interestingly, IL-6 receptor inhibition by tocilizumab, a recombinant humanized monoclonal antibody, reversed liver injury during CRS[68]. In addition, clinical evidence suggests that inhibition of the inflammatory response in SARS-CoV-2-related CRS ameliorates the course of infection [69] . Data from the MERS-CoV outbreak showed that IL-6 and pro-inflammatory cytokines like IL-2 played important roles in infection and liver injury [70] . In patients with COVID-19, increased IL-6 concentration and other cytokine signatures have been identified[71], correlating with loss of lung function, lung injury, and poor outcomes [72] . As such, it seems that SARS-CoV-2 strongly drives a lethal systemic cytokine response in some patients (as in CRS), although factors that regulate this response are not well understood. This cytokine response is involved in disease severity and patient outcome [73] . Immune pathway hyperactivation and inflammation associated with a cytokine storm in SARS-CoV-2 infection can damage many other organs, such as the gut and liver, through Th17 and CD8 T cells and the activation of inflammatory responses[3,36,74].

Various biomarkers are directly associated with liver injury and indirectly with COVID-19 severity and prognosis. Trends in biomarker research over the course of the disease may help physicians recognize the conditions associated with COVID-19 more quickly and accurately. Liver enzymes, including ALT and AST, are useful biomarkers of hepatic injury in COVID-19 patients [75] . Liver diseases primarily lead to mild clinical symptoms but must be diagnosed early. Hepatic dysfunction could be evaluated by biomarkers that are correlated with liver function (e.g., albumin) and hepatocyte integrity (e.g., ALT and AST), while some are correlated with conditions related to the biliary tract (e.g., ALP and GGT) [75] .

The serum levels of several clinical biomarkers such as liver enzymes (e.g., ALT and AST) are elevated in COVID-19 patients. Moreover, recent findings have shown that lactate dehydrogenase (LDH) concentration increases in COVID-19 patients and is significantly higher in patients with increased ALT relative to patients with normal ALT [76, 77] . This phenomenon may occur because of cell apoptosis induced by SARS-CoV-2 infection or because of the use of antiviral drugs. It is suggested that the elevated level of LDH reflects the status of liver function and other organs in response to anti-influenza activity of antiviral compounds [78] . Uchide et al [79] also reported that the apoptosis caused by influenza infection was correlated with increasing LDH levels. Moreover, LDH is known as a marker of lung and hepatobiliary diseases. Thus, a marked elevation in LDH values in patients with increased ALT could be indicate the involvement of the lungs and liver. As a critical component of the immune system, CRP is produced in the liver in response to a variety of inflammatory cytokines [80] . Recent studies have shown that an increase of CRP level is detected in almost 80% of patients with COVID-19 [81, 82] . In addition, a study comparing patients with elevated ALT normal ALT activities found no significant between-group difference in CRP values. Inconsistent with that finding, Li et al [77] found that elevated CRP levels were associated with hepatic dysfunction and increased ALT levels in COVID-19 patients. These discrepancies may be the result of differences in sample sizes and CRP detection kits. In addition, elevated serum ferritin and CRP are particularly useful in prediction of COVID-19 progression or exacerbated secondary bacterial infection, cytokine storm with multiorgan failure, and poor outcome[83].

COVID-19 usually presents as viral pneumonia with primary symptoms of fever, cough, and shortness of breath. However, some patients may develop extrapulmonary signs and symptoms in their clinical picture. Of those, GI and hepatic manifestations are most noticeable [84, 85] . Some studies reported that GI symptoms were seen in 26%-53% of COVID-19 patients at any time during their illness. Diarrhea, nausea, vomiting, abdominal pain, anorexia, anosmia, and dysgeusia are among the symptoms reported in decreasing order of prevalence [86] [87] [88] . According to the largest, most recent, and most comprehensive systematic reviews, GI symptoms are present in 10%-15% of coronavirus cases, and include diarrhea, 7.7%-9%; nausea/vomiting, 6%-7.8%; loss of appetite, 21%; and abdominal pain, 2.7%-3% [12, 89] . Interestingly, few patients with coronavirus infection present with GI symptoms as their only clinical picture or ahead of pulmonary manifestations. On average, 3%-16% of COVID-19 cases may present with digestive symptoms per se in the absence of respiratory symptoms[43,90,91].

Hepatic enzyme derangements are considered as the most common extrapulmonary findings in the context of COVID-19[92]. The incidence of an abnormal liver function test in this context varies from 1% to 76% in the published literature[93-96]. However, three large, recent meta-analyses found that the incidence and prevalence of abnormal liver function tests among COVID-19 patients were 23.1% and 15%-19%, respectively [12, 89, 97] . Despite the presence of ACE2 receptors on cholangiocytes, the liver injury in such patients was primarily hepatocellular rather than cholestatic, as indicated by elevations in ALT, AST, and LDH levels [60] . A retrospective study evaluating more than 1800 COVID-19 patients at admission and during the hospital course reported enzyme abnormality prevalences of AST 66.9%, ALT 41.6%, and ALP 13.5% at admission with peaks of AST 83.4%, ALT 61.6%, and ALP 80% during hospitalization [84] . Enzyme elevation is usually mild, i.e. 1-2 times the upper limit of normal (ULN); nevertheless, moderate (2-5 times the ULN) and severe (more than 5 times the ULN) elevations of AST and ALT have sometimes been reported. The GGT concentration may also be increased at admission and even escalate during hospitalization. However, that enzyme is not unique to the liver and is distributed in many other tissues including the kidneys, pancreas, spleen, heart, brain, and seminal vesicles. Despite mild elevations in the total bilirubin level, jaundice is rarely seen in COVID-19 patients [86, 96, 98] . The severity of COVID-19 appears to be associated with increased AST, ALT, and ALP concentrations, as well as a fall in albumin level [84, 96, 99, 100] .

To date, no case of acute liver failure (ALF) has been proven to be directly caused by COVID-19. There is only one suspected case of ALF in the context of coronavirus infection [101] . Approximately 3% of all cases of COVID-19 and 3.9% of those with severe COVID-19 have pre-existing chronic liver diseases [97, 100] . Few studies concluded that the underlying liver disease, including nonalcoholic fatty liver disease, were associated with more pronounced COVID-19 severity or mortality compared with those with no pre-existing hepatic disorders. Furthermore, a recent meta-analysis failed to find a direct association. Therefore, whether the presence of the underlying liver disease may change the outcome of patients with COVID-19 remains to be shown [97, [102] [103] [104] .

Presumably, liver transplant patients are more vulnerable to coronavirus infection because of their potent immunosuppressive drug regimens. An international registry study (SECURE-Cirrhosis) evaluated 151 Liver transplant recipients with confirmed SARS-CoV-2 infection. The rate of intensive care unit admission and need for invasive ventilation was more frequent in liver transplant patients. However, unlike a few other studies, the study failed to demonstrate that organ transplantation significantly increased the risk of death in the included cases[105-109].

The global outbreak of COVID-19 has led to the aggregation of pivotal data on the clinical and epidemiological characteristics of the disease. A number of studies on the topic have revealed that COVID-19 patients can present with different stages of liver disease [110, 111] . Cai et al [96] recognized that about half of the patients with COVID-19 showed liver functional test derangements at admission, almost 90% having a mild pattern of liver enzyme elevation, and about 25% had transaminase levels of more than three times the ULN during hospitalization [110, 111] . The most common abnormality in liver function tests has been hypoalbuminemia. Although changes in the levels of liver-related blood factors may be caused by direct viral damage, many August 6, 2021

Volume 9 Issue 22 studies have reported that the use of various drugs during hospitalization caused the abnormalities. Drugs that may be responsible include antivirals such as arbidol, favipiravir, remdesivir, and others; steroids; and antipyretics like acetaminophen or nonsteroid anti-inflammatory drugs [41, 112] . Favipiravir is an antiviral drugs that was approved in Japan as a standard treatment for patients with influenza. Favipiravir, also known as T-705, is a pro-drug that is converted to its active metabolite, favipiravir ibofuranosyl-5′-triphosphate, by intracellular phosphorylation. It is a purine nucleotide that is recognized by and inhibits RNA-dependent RNA polymerase. [117] . Recent studies have reported elevated levels GGT and total bilirubin in hospitalized patients treated with lopinavir/ritonavir, so it should be avoided or used with great caution in patients with a history of metabolic liver disease [117] . Several studies have highlighted the key role of antiviral drugs targeting COVID-19 in liver dysfunction (Figure 2 ). For example, Jiang et al [118] found that lopinavir/ ritonavir use in COVID-19 patients was associated with liver injury and abnormal liver function, particularly in patients with noncritical disease. Cai et al [96] reported a marked increase in transaminase levels during hospitalization. Approximately 11% of patients had ALT levels greater than three times the ULN, and about 12% had GGT levels of up to three times the ULN. Lopinavir and ritonavir represent the most important risk factor for liver disease because they leads to a four-fold elevation in the likelihood of hepatic failure [110, 111] .

Cytochromes P450 (CYPs) are a superfamily of monooxygenase enzymes that mediate clinically relevant drug interactions in various pathological conditions [119] . There is strong support for the hypothesis that the metabolic activity of CYPs will undoubtedly be altered (mostly downregulated) throughout the course of SARS-CoV-2 infection in a similar pattern, leading to a clearance-related pharmacokinetic interaction with the antiviral drugs that are administered. Additionally, liver involvement in SARS-CoV-2 infection may further complicate the clinical course of the disease. In May 2020, the investigational antiviral agent, remdesivir, which was once offered against Ebola, was authorized for emergency use by the United States Food and Drug Administration (FDA) for the treatment of COVID-19. Remdesivir is extensively metabolized by CYPs, particularly CYP3A4. Furthermore, other potential therapeutic candidates for treating COVID-19 including chloroquine [120] and colchicine [121] are also metabolized by enzymes within the liver. A sound understanding of the mechanism of such crosstalk is essential as it may affect the therapeutic/toxic reaction of patients to the agents [122] . Caution should be exercised when anti-cytokine treatment is administered. In this respect, partial or full restoration of normal metabolic conditions can be achieved as a consequence of the immunomodulatory response.

It is well known that use of remdesivir considerably reduces time to recovery of hospitalized COVID-19 patients[123]. Among COVID-19 patients treated with remdesivir, reversible grade 1-2 ALT/AST elevations were seen without pathologic abnormalities in either liver or kidney function. Marked increase in AST and ALT levels were reported in 6% of patients, and life-threatening situations associated with increased AST/ALT levels were present in 2%, which led to a recommendation to reduce or discontinue long-term remedesiver therapy [124] . That is in line with other data that mild hepatocellular injury in the form of increased AST/ALT levels did not progress to ALF in patients without pre-existing chronic liver injury. Therefore, remedesiver can be used with close monitoring of liver toxicity especially in patients with pre-existing liver disease [125] .

A recent placebo-controlled study evaluated the protective effect of intravenous remdesivir in hospitalized adult patients with severe COVID-19. It reported premature cessation of treatment in more remdesivir recipients than placebo recipients because of adverse events such as elevation of aminotransferase or bilirubin level. In spite of the August 6, 2021

Volume 9 Issue 22 association of SARS-CoV-2 infection with hepatic dysfunction, the study found an increased risk of liver damage with remdesivir compared with other therapeutic agents. However, because of the current FDA and European medicines agency approvals to prescribe remdesivir for patients with COVID-19, physicians should be aware of this plausible association and must initiate adequate hepatic monitoring [126] . Considering the fact that there is yet to be a completely effective antiviral therapy for COVID-19, antiviral agents including oseltamivir, arbidol, lopinavir, and ritonavir are used in about half of the serious COVID-19 cases [112] . These antiviral drugs may cause abnormal liver function. Moreover, ribavirin-induced hemolysis might give rise to tissue hypoxia, which may also cause increased serum liver enzyme levels. The preexistence of chronic liver disease (e.g., hepatitis B or hepatitis C) with or without elevated transaminase levels could pose additional risk of drug-induced liver damage [127] . Accordingly, in patients with pre-existing liver disease, antipyretic drugs, traditional herbal medicines, antiviral medicines or antibiotics should be used cautiously; physicians must take into consideration the risk of liver damage deterioration. For instance, doxycycline is a broad-spectrum tetracycline-class antibiotic that chelates zinc, which is required by the matrix metalloproteinases involved in COVID-19 infection, and inhibits SARS-CoV-2 RNA polymerase activity and viral entry. Doxycycline is a viral serine protease inhibitor that has broad spectrum of antiviral activity including SARS-CoV-2. It exerts anti-inflammatory effects by downregulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Likewise, reduction of secretion of inflammatory cytokines such as tumor necrosis factor-α, IL-1b, and IL-6, and induction of mast cells apoptosis is observed [128] . Hepatotoxicity is seen with doxycycline use, but doxycycline is potentially less hepatotoxic than tetracycline. This medicine is generally safe and effective but has been linked to occasional obviating bile duct injuries [129] . In addition, other studies linking doxycycline with hepatotoxicity reported abrupt hepatic failure and hepatocellular necrosis in patients using potentially hepatotoxic agents, after initiating doxycycline therapy 129] .

An increasing number of studies have described azithromycin-induced hepatotoxicity. Azithromycin is a macrolide antibiotic that used for the treatment of Grampositive and Gram-negative bacterial infections. Azithromycin has synergistic antiviral activity associated with enhanced production of interferon (IFN)-β and IFN-λ and related cytosolic genes that contribute to virus recognition [130] . Azithromycin in vitro and in vivo antiviral activity, especially against respiratory syncytial virus and influenza viruses [130, 131] , suggests promising antiviral effect against early stage of COVID-19 [132] .

Like any medication, Azithromycin can have adverse effects on the hepatobiliary system including symptoms and signs of cholestatic hepatitis such as fever, fatigue, jaundice, pruritus, and eosinophilia. However very few reported cases with complications of vanishing bile duct syndrome and hepatic failure requiring liver transplantation have been associated with azithromycin use [133] .

Tocilizumab is approved for use in the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. Although it is not a specific antiviral agent, some researchers have recently suggested tocilizumab for the treatment of severe CRS in COVID-19 patients [68, 134] . Tocilizumab is a recombinant humanized monoclonal antibody that blocks the IL-6 signal transduction pathway [68] . The most common set of side effects of tocilizumab are headache, hypertension, and rare occurrences of hepatotoxicity ranging from mild elevation of liver enzymes to serious drug-induced hepatotoxicity [135] . Currently, data on tocilizumab-induced hepatotoxicity in COVID-19 patients have not been established. The evidence shows that tocilizumab might be effective in severe COVID-19, even in patients with elevation of serum transaminase levels of up to 5-fold the ULN and GGT levels of up to ten-fold the ULN. When possible, a baseline liver biopsy is recommended prior to tocilizumab treatment in patients with liver dysfunction to diminish the potentially detrimental effect of other antiviral medicines on liver function during SARS-CoV-2 infection. Some studies reported that the systemic inflammatory reaction to the drugs used in the treatment of SARS-CoV-2 infection and pneumonia might induce liver injury in COVID-19 patients [136] . Larger studies are required to confirm the safety of tocilizumab therapy and to validate its use in chronic liver disease patients [111] .

The COVID-19 pandemic is a worldwide threat to human health and global stability. Extensive study has found that in addition to the respiratory system, the digestive tract and liver are involved in SARS-CoV-2 infection. Immune-mediated viral damage, drug-induced hepatotoxicity, secondary liver injury induced by an overwhelming systemic inflammatory reaction, and the deterioration of pre-existing liver injury are leading causes of liver damage in COVID-19. Physicians need to pay particular attention to the management of pre-existing liver injury, the monitoring of liver function, the provision of robust supportive treatment, and minimization of the risk of drug-induced hepatotoxicity in COVID-19 patients.

For all COVID-19 patients, biochemical markers of liver injury, including ALT/AST, bilirubin, albumin, and prothrombin time, should be evaluated to detect liver damage. If plasma LDH and AST values are increased but the ALT value is within the normal range, skeletal muscle or cardiac injury rather than liver damage should be considered. Given that liver failure is also a major risk factor among elderly patients with COVID-19, caregivers need to pay particular attention to the management of hepatic comorbidities (Table 1 ). In the management of COVID-19 patients with hepatitis B, stopping antiviral treatment should be avoided to prevent the reactivation of hepatitis B, and antihepatitis B virus drugs should be monitored when patients are given glucocorticoid treatment.

Thus, in the case of severe liver injury in COVID-19 patients, a meticulous evaluation to recognize any underlying disease is needed, and the degree of abnormality in liver function should be recorded to manage the onset of liver failure. The initial screening consists of a careful history of hepatic comorbidities, hepatotoxin exposure (e.g., alcohol, drugs, herbs, and chemicals), hypoxia, and circulation quality. Circulatory and respiratory mechanical support should be considered for COVID-19 patients with hypoxic hepatitis [83] .

Administration of L-ornithine-L-aspartate as a promising agent in the management of liver failure could be effective in reducing ammonia levels in hepatic encephalopathy. However, those remedies are only a complementary treatment and should not be overemphasized. Hence, both prebiotics and probiotics could provide various health benefits by regulating the microecological balance and bacterial activity in the intestine [130] . Administration of silymarin 420 mg/d and ursodeoxycholic acid 500 mg/d protect hepatic function from injury, especially if SARS-CoV-2 infection is correlated with increasing serum transaminase levels and serum total bilirubin [133] .

A recent study by Ibrahim et al [137] showed that N-acetyl-cysteine (NAC), a drug that reduces the risk of chronic obstructive pulmonary disease, could be used in COVID-19 patients who lack G6PD deficiency. NAC elicited an improvement in clinical manifestations together with an obvious drop in CRP and ferritin levels in COVID-19 patients; rebound increases were seen upon discontinuation of NAC. Resuming intravenous administration of NAC for two additional intervals led to repeated reductions in CRP and ferritin levels as markers of inflammation. NAC administration accelerated the discontinuation of extracorporeal membrane oxygenation (ECMO) and eventual hospital discharge of the patient. In addition, NAC blocked hemolysis and liver enzyme elevation and facilitated removal from the ventilator and venovenous ECMO, leading to full recovery of COVID-19 patients with G6PD deficiency. The mechanism of action of NAC may consist of viral infection blockade and averting the ensuing uncontrolled cytokine storm. Further studies of this agent are needed. As with other viral infections, liver transplant recipients are at an increased risk of infection with SARS-CoV-2 through hospital exposure during the outbreak [138] . Recipients of liver transplantation may have a strong potential to develop a severe immunosuppressive response, postoperative infection, multiple organ failure, and mortality. There exists a contradiction such that excessive immunosuppression therapy results in acute infections, whereas exposure to insufficient immunosuppression leads to graft loss through the rejection reaction. A study by Qin et al [139] showed that recipients of liver transplantation had a prolonged period of being a virus carrier. Even if the initial SARS-CoV-2 testing is negative during the treatment, there is a chance of a subsequent positive result because of a rise in the viral load accompanying the increased dosage of immunosuppressive drugs. Strict screening guidance and extended follow-up are recommended for recipients of liver transplantation with SARS-CoV-2 infection. Research has shown that corticosteroid treatment of COVID-19 patients with advanced liver disease should be used with caution. In severe respiratory cases of COVID-19, low-dose methylprednisolone may August 6, 2021

Volume 9 Issue 22 be useful, particularly with increasing lung infiltrates and deteriorating clinical outcome even with invasive mechanical ventilation. Hence, its use is still controversial and in this situation, physicians should pay more attention to hepatic damage in COVID-19 patients [140] .

COVID-19 is associated with respiratory symptoms, digestive complications, and liver injury. Severe inflammatory response, anoxia, drug-induced liver injury, direct cytotoxicity, and reactivation of pre-existing liver disease might be the etiologic mechanisms behind liver injury in COVID-19 patients (Figure 3 ). In this review, we summarized the clinical manifestations and liver-related events seen in COVID-19 patients, including the pathophysiology, etiology, biomarkers, diagnosis, treatment, and management strategies for liver injury. We aimed to increase the awareness of healthcare workers about liver injury and to provide information for hepatic management in COVID-19 patients . Physicians should (1) pay special attention to the management of concurrent metabolic liver disorders, (2) boost hepatic function by strengthening supportive therapy, and (3) minimize the risk of druginduced liver injury. SARS-CoV-2 infection features strong transmission ability and a prolonged incubation time, eliciting an extraordinary threat to human life through various clinical manifestations. SARS-CoV-2 infection can result in liver damage that is associated with the progression of the disease and influences the diagnosis, prognosis, and treatment. Along these lines, liver transplant recipients who acquire COVID-19 have a poor prognosis and a higher risk of mortality. COVID-19-related liver injury can result from moderate microvascular steatosis, severe dehydration, viral infection, hepatotoxic antiviral drugs, the SIRS, acute hypoxemic respiratory failure, and multiple organ failure. SARS-CoV-2 invades the liver directly, causing hepatocyte damage and viral microvascular steatosis. Importantly, ACE2 receptors are highly expressed in liver tissue and play an important role in the hepatobiliary system. Additionally, physicians should pay special attention to protecting the hepatobiliary system over the course of COVID-19 treatment. Some countries have begun SARS-CoV-2 vaccination, which will combat the spread of the disease and may prevent the August 6, 2021 Volume 9 Issue 22 associated liver damage. Patients should be persuaded to continue their treatments to manage their pre-existing liver diseases. Close monitoring of liver function in COVID-19 patients and the use of diverse therapeutic interventions can blunt liver injury in patients with pre-existing liver diseases and thereby decrease mortality. Additional research is urgently needed to more precisely clarify host-pathogen crosstalk, host immune mechanisms, and mechanisms of viral attachment to host immune cells.

Clearly, further investigation of the mechanisms, manifestations, and prognosis of liver injury in patients with COVID-19 is needed to facilitate the development of targeted treatments to improve the patient condition.

The cytokine storm and COVID-19

COVID-19: Abnormal liver function tests

Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19

Hepatic manifestations of COVID-19

Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies

Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis

Acute Liver Failure in a COVID-19 Patient Without any Preexisting Liver Disease

Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study

Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19

Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study

Gastrointestinal and Hepatic Manifestations of COVID-19: Evolving Recognition and Need for Increased Understanding in Vulnerable Populations

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

COVID-19 in solid organ transplant recipients: A single-center case series from Spain

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

COVID-19 in solid organ transplantation patients: A systematic review

Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study

Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design

Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms

ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report

GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Liver injury in remdesivir-treated COVID-19 patients

Hepatic Disorders With the Use of Remdesivir for Coronavirus

Etiology and management of liver injury in patients with COVID-19

Therapeutic Potential for Tetracyclines in the Treatment of COVID-19

Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study

Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation

Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 Levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis

Azithromycin for COVID-19: More Than Just an Antimicrobial?

Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective

Off-label use of tocilizumab in patients with SARS-CoV-2 infection

First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous Nacetylcysteine

Liver Injury in COVID-19: Caution and Management

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

Wang XH; , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team; Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

Tocilizumab and COVID-19

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report

Polygalasaponin F treats mice with pneumonia induced by influenza virus

Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells

Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury

Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature

Protective effect of bicyclol on lipopolysaccharide-induced acute lung injury in mice

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

Current pharmacological treatments for COVID-19: What's next?

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity

COVID-19: A review of the proposed pharmacological treatments

Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis

Chloroquine attenuates paraquat-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis

Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055

The gut microbiota and host health: a new clinical frontier

Contributions of the intestinal microbiome in lung immunity

Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19

Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study

Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?

From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR)

Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT)

Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke

Could Vitamins Help in the Fight Against COVID-19?

Role of vitamin E in nonalcoholic fatty liver disease

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies

Potential protection of vitamin C against liver-lesioned mice

Zinc and COVID-19: Basis of Current Clinical Trials

Zinc and liver disease

Possibility of magnesium supplementation for supportive treatment in patients with COVID-19

Magnesium and liver disease

COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2

Is copper beneficial for COVID-19 patients?

Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats

Corticosteroids in Acute Lung Injury: The Dilemma Continues